161 related articles for article (PubMed ID: 21277009)
21. Significance of cholecystectomy in cytoreductive surgery for advanced ovarian cancer.
Son JH; Dong SR; Kim J; Kim J; Kong TW; Chang SJ
BMC Surg; 2023 Mar; 23(1):60. PubMed ID: 36941661
[TBL] [Abstract][Full Text] [Related]
22. Porta hepatic schwannoma: case report and a 30-year review of the literature yielding 15 cases.
Yin SY; Zhai ZL; Ren KW; Yang YC; Wan DL; Liu XY; Wang LJ; Zheng SS
World J Surg Oncol; 2016 Apr; 14():103. PubMed ID: 27038921
[TBL] [Abstract][Full Text] [Related]
23. Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182.
Rodriguez N; Miller A; Richard SD; Rungruang B; Hamilton CA; Bookman MA; Maxwell GL; Horowitz NS; Krivak TC
Gynecol Oncol; 2013 Sep; 130(3):487-92. PubMed ID: 23791702
[TBL] [Abstract][Full Text] [Related]
24. Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival.
Cohen JG; Tran AQ; Rimel BJ; Cass I; Walsh CS; Karlan BY; Li AJ
Gynecol Oncol; 2014 Mar; 132(3):556-9. PubMed ID: 24423879
[TBL] [Abstract][Full Text] [Related]
25. Long-term Survivors After Liver Resection for Ovarian Cancer Liver Metastases.
Bacalbaşa N; Balescu I; Dima S; Popescu I
Anticancer Res; 2015 Dec; 35(12):6919-23. PubMed ID: 26637917
[TBL] [Abstract][Full Text] [Related]
26. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas.
Chi DS; Zivanovic O; Levinson KL; Kolev V; Huh J; Dottino J; Gardner GJ; Leitao MM; Levine DA; Sonoda Y; Abu-Rustum NR; Brown CL; Barakat RR
Gynecol Oncol; 2010 Oct; 119(1):38-42. PubMed ID: 20609464
[TBL] [Abstract][Full Text] [Related]
27. [How to increase the optimal rate of secondary cytoreductive surgery in recurrent epithelial ovarian cancer].
Li YF; Li MD; Liu FY; Liu JH; Li JD
Ai Zheng; 2003 Nov; 22(11):1193-6. PubMed ID: 14613651
[TBL] [Abstract][Full Text] [Related]
28. Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes.
Eriksson AGZ; Graul A; Yu MC; Halko A; Chi DS; Zivanovic O; Gardner GJ; Sonoda Y; Barakat RR; Abu-Rustum NR; Leitao MM
Gynecol Oncol; 2017 Aug; 146(2):263-267. PubMed ID: 28527673
[TBL] [Abstract][Full Text] [Related]
29. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.
Benedetti Panici P; De Vivo A; Bellati F; Manci N; Perniola G; Basile S; Muzii L; Angioli R
Ann Surg Oncol; 2007 Mar; 14(3):1136-42. PubMed ID: 17195909
[TBL] [Abstract][Full Text] [Related]
30. Optimal cytoreduction after combined resection and radiofrequency ablation of hepatic metastases from recurrent malignant ovarian tumors.
Mateo R; Singh G; Jabbour N; Palmer S; Genyk Y; Roman L
Gynecol Oncol; 2005 Apr; 97(1):266-70. PubMed ID: 15790474
[TBL] [Abstract][Full Text] [Related]
31. Surgery in recurrent epithelial ovarian cancer: benefits on Survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction.
Tian WJ; Jiang R; Cheng X; Tang J; Xing Y; Zang RY
J Surg Oncol; 2010 Mar; 101(3):244-50. PubMed ID: 20112269
[TBL] [Abstract][Full Text] [Related]
32. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
33. The role of liver resection at the time of secondary cytoreduction in patients with recurrent ovarian cancer.
Kolev V; Pereira EB; Schwartz M; Sarpel U; Roayaie S; Labow D; Momeni M; Chuang L; Dottino P; Rahaman J; Zakashansky K
Int J Gynecol Cancer; 2014 Jan; 24(1):70-4. PubMed ID: 24356412
[TBL] [Abstract][Full Text] [Related]
34. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.
Suidan RS; Ramirez PT; Sarasohn DM; Teitcher JB; Iyer RB; Zhou Q; Iasonos A; Denesopolis J; Zivanovic O; Long Roche KC; Sonoda Y; Coleman RL; Abu-Rustum NR; Hricak H; Chi DS
Gynecol Oncol; 2017 Apr; 145(1):27-31. PubMed ID: 28209497
[TBL] [Abstract][Full Text] [Related]
35. Retrospective analysis of outcomes of secondary debulking surgery for recurrent epithelial ovarian cancer with favorable prognostic factors.
Nasu K; Kai K; Hirakawa T; Nishida M; Matsumoto H; Kawano Y; Narahara H
J Obstet Gynaecol Res; 2014 Mar; 40(3):791-6. PubMed ID: 24245582
[TBL] [Abstract][Full Text] [Related]
36. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
Tebes SJ; Sayer RA; Palmer JM; Tebes CC; Martino MA; Hoffman MS
Gynecol Oncol; 2007 Sep; 106(3):482-7. PubMed ID: 17590420
[TBL] [Abstract][Full Text] [Related]
37. The role of F18-FDG PET/CT in predicting secondary optimal de-bulking in patients with recurrent ovarian cancer.
Amit A; Hodes A; Lavie O; Keidar Z; Matanes E; Lowenstein L
Surg Oncol; 2017 Dec; 26(4):347-351. PubMed ID: 29113651
[TBL] [Abstract][Full Text] [Related]
38. Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.
Cowan RA; Tseng J; Murthy V; Srivastava R; Long Roche KC; Zivanovic O; Gardner GJ; Chi DS; Park BJ; Sonoda Y
Gynecol Oncol; 2017 Nov; 147(2):262-266. PubMed ID: 28888540
[TBL] [Abstract][Full Text] [Related]
39. Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction.
Di Donato V; Giannini A; D'Oria O; Schiavi MC; Di Pinto A; Fischetti M; Lecce F; Perniola G; Battaglia F; Berloco P; Muzii L; Benedetti Panici P
Ann Surg Oncol; 2021 Jan; 28(1):222-230. PubMed ID: 32779050
[TBL] [Abstract][Full Text] [Related]
40. Challenges of cytoreduction in porta hepatis in surgery for advanced ovarian cancer.
Raju K; Jonnada PK; Badude M; Nekkanti S; Nusrath S; Keshri P; Ram Reddy R
Gynecol Oncol Rep; 2024 Aug; 54():101413. PubMed ID: 38854685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
